Zacks Investment Research downgraded shares of Catalent (NYSE:CTLT) from a buy rating to a hold rating in a report released on Friday.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
CTLT has been the topic of several other research reports. Goldman Sachs Group assumed coverage on Catalent in a report on Wednesday, January 24th. They set a buy rating and a $50.00 price target on the stock. Royal Bank of Canada set a $48.00 price target on Catalent and gave the company a buy rating in a report on Monday, February 5th. Stephens downgraded Catalent from an overweight rating to an equal weight rating in a report on Tuesday, February 6th. Bank of America increased their price target on Catalent from $47.00 to $49.00 and gave the company a buy rating in a report on Tuesday, February 6th. Finally, First Analysis assumed coverage on Catalent in a report on Friday, January 5th. They set an equal weight rating on the stock. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $45.40.
Catalent (NYSE CTLT) traded up $0.87 during trading hours on Friday, reaching $42.93. The company had a trading volume of 670,728 shares, compared to its average volume of 911,922. Catalent has a 12-month low of $27.48 and a 12-month high of $47.87. The firm has a market capitalization of $5,606.05, a P/E ratio of 26.28, a P/E/G ratio of 2.41 and a beta of 1.54. The company has a quick ratio of 1.78, a current ratio of 2.22 and a debt-to-equity ratio of 2.66.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Monday, February 5th. The company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The firm had revenue of $606.30 million for the quarter, compared to the consensus estimate of $565.05 million. During the same quarter in the prior year, the company posted $0.27 earnings per share. The firm’s revenue was up 25.3% on a year-over-year basis. equities analysts predict that Catalent will post 1.53 earnings per share for the current year.
In related news, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.70% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of CTLT. American Century Companies Inc. lifted its holdings in shares of Catalent by 755.3% during the fourth quarter. American Century Companies Inc. now owns 2,631,643 shares of the company’s stock valued at $108,108,000 after acquiring an additional 2,323,971 shares during the period. Eagle Asset Management Inc. lifted its holdings in shares of Catalent by 290.9% during the third quarter. Eagle Asset Management Inc. now owns 1,153,710 shares of the company’s stock valued at $47,636,000 after acquiring an additional 858,600 shares during the period. Redmile Group LLC lifted its holdings in shares of Catalent by 464.2% during the fourth quarter. Redmile Group LLC now owns 833,063 shares of the company’s stock valued at $34,222,000 after acquiring an additional 685,400 shares during the period. Carillon Tower Advisers Inc. bought a new position in shares of Catalent during the fourth quarter valued at $27,561,000. Finally, Hood River Capital Management LLC bought a new position in shares of Catalent during the fourth quarter valued at $16,283,000. 99.03% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/03/10/catalent-ctlt-downgraded-by-zacks-investment-research-to-hold-2.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.